Researchers, Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. from the Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX. studied the efficacy of cyclophosphamide (CP)-based metronomic chemotherapy in men who have docetaxel-resistant hormone-refractory prostate cancer (HRPC).

To be included in the study men have to have confirmed metastatic HRPC and have disease progression while being under docetaxel-based chemotherapy. The study’s primary endpoint was prostate-specific antigen (PSA) response. Secondary endpoints were survival and toxicity.

Low-dose CP (50 mg/d) and dexamethasone (1 mg/d) were given in a metronomic manner (low dose). Treatment was continued until disease progression or intolerable side effects occurred.

A total of seventeen men were enrolled in this study. The median follow-up was 12 weeks (range: 4-60). Median age was 68 years (range: 42-85). Median PSA at study entry was 134 ng/ml (range: 46.0-6554).

Nine men had a PSA response (median 44.4%); four men had a greater than 50% response and five men had a less than 50% PSA response. Eight men eventually experienced a PSA progression. The overall